Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis

INTRODUCTION: Deucravacitinib, an oral tyrosine kinase 2 (TYK2) inhibitor, is approved in the United States to treat adults with moderate-to-severe plaque psoriasis (PsO). This study compared the long-term efficacy of deucravacitinib and adalimumab using results from long-term extension (LTE) trials...

Descripción completa

Detalles Bibliográficos
Autores principales: Armstrong, April W., Park, Sang Hee, Patel, Vardhaman, Hogan, Malcolm, Wang, Wei-Jhih, Davidson, David, Chirikov, Viktor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613163/
https://www.ncbi.nlm.nih.gov/pubmed/37525000
http://dx.doi.org/10.1007/s13555-023-00977-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613163/
https://www.ncbi.nlm.nih.gov/pubmed/37525000
http://dx.doi.org/10.1007/s13555-023-00977-1

Ejemplares similares